ES2588204T3 - Inhibidores de la proteasa de HCV - Google Patents
Inhibidores de la proteasa de HCV Download PDFInfo
- Publication number
- ES2588204T3 ES2588204T3 ES09849606.0T ES09849606T ES2588204T3 ES 2588204 T3 ES2588204 T3 ES 2588204T3 ES 09849606 T ES09849606 T ES 09849606T ES 2588204 T3 ES2588204 T3 ES 2588204T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- heteroaryl
- aryl
- heterocycloalkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto de la fórmula siguiente:**Fórmula** en la que R1 es -H, -OH, alquilo C1-6, alcoxilo C1-6, cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, heteroarilo, o -NH-Z-R; en la que R es H, o es un resto seleccionado de alquilo C1-6, cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, y heteroarilo, cada uno de los cuales está opcionalmente mono-, di-, o tri-sustituido con halógeno, nitro, ciano, amino, alquilo C1-6, alcoxilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, o heteroarilo; y Z es -C(O)-, -C(O)O-, -C(O)C(O)O-, -C(O)C(O)NH-, - C(O)NR'-, -OC(S)-, - C(S)NR'-, o -C(NH)O-, R' es H, alquilo C1-6, cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, o heteroarilo; R2 es H, o es un resto seleccionado de alquilo C1-6, cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, y heteroarilo, cada uno de los cuales está opcionalmente mono-, di-, o tri-sustituido con halógeno, nitro, ciano, amino, alquilo C1-6, alcoxilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, o heteroarilo; A es N o CH; U es -O-, -NH-, -NH(CO)-, -NHSO-, o -NHSO2-; W es -(CH2)m-, -NH(CH2)n-, -(CH2)nNH-, -O(CH2)n-, -(CH2)nO-, -S(CH2)n-, -(CH2)nS-, -SO-, -SO(CH2)n-, -(CH2)nSO-, - SO2(CH2)n-, o -(CH2)nSO2-, m es 1, 2, o 3 y n es 0, 1, o 2; X es -O-, -S-, o -NH-; y Y es o , en los que cada V y T, independientemente, es -CH- o -N-; cada A1 y A2, independientemente, es un resto seleccionado de cicloalquilo C4-10, heterocicloalquilo C1-10, arilo, y heteroarilo, cada uno de los cuales está opcionalmente mono-, di-, o tri-sustituido con halógeno, nitro, ciano, amino, alquilo C1-6, alcoxilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, o heteroarilo, o condensado opcionalmente con cicloalquilo C3-10, heterocicloalquilo C2-10, arilo, o heteroarilo; y Ri es H, halógeno, nitro, ciano, o amino, o es un resto seleccionado de alquilo C1-6, alcoxilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, y heteroarilo, cada alquilo C1-6, alcoxilo C1-6, alquenilo C2-6, y alquinilo C2-6 está opcionalmente mono-, di-, o trisustituido con halógeno, nitro, ciano, amino, alquilo C1-6, alcoxilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, o heteroarilo, y cada cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, y heteroarilo está opcionalmente mono-, di-, o tri-sustituido con halógeno, nitro, ciano, amino, alquilo C1-6, alcoxilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, o heteroarilo, o condensado opcionalmente con cicloalquilo C3-10, heterocicloalquilo C1-10, arilo, o heteroarilo.
Description
Más adelante se muestran 281 compuestos ejemplares de esta invención.
Compuesto 1 Compuesto 2 Compuesto 3
Compuesto 4 Compuesto 5 Compuesto 6
Compuesto 7 Compuesto 8 Compuesto 9
Compuesto 10 Compuesto 11 Compuesto 12
Compuesto 13 Compuesto 14 Compuesto 15
7
Compuesto 16 Compuesto 17
Compuesto 19 Compuesto 20
Compuesto 22 Compuesto 23
Compuesto 25 Compuesto 26
Compuesto 28 Compuesto 29 Compuesto 18
Compuesto 21
Compuesto 24
Compuesto 27
Compuesto 30
8
Compuesto 46 Compuesto 47
Compuesto 49 Compuesto 50
Compuesto 52 Compuesto 53
Compuesto 55 Compuesto 56
Compuesto 58 Compuesto 59 Compuesto 48
Compuesto 51
Compuesto 54
Compuesto 57
Compuesto 60
10
Compuesto 121 Compuesto 122 Compuesto 123
Compuesto 124 Compuesto 125 Compuesto 126
Compuesto 127 Compuesto 128 Compuesto 129
Compuesto 130 Compuesto 131 Compuesto 132
Compuesto 133 Compuesto 134 Compuesto 135
15
Compuesto 196 Compuesto 197 Compuesto 198
Compuesto 199 Compuesto 200 Compuesto 201
Compuesto 202 Compuesto 203 Compuesto 204
Compuesto 205 Compuesto 206 Compuesto 207
Compuesto 208 Compuesto 209 Compuesto 210
20
Claims (2)
-
imagen1 imagen2 imagen3 imagen4 imagen5 Compuesto 19 Compuesto 20Compuesto 22 Compuesto 23Compuesto 25 Compuesto 26Compuesto 28 Compuesto 29Compuesto 31 Compuesto 32 Compuesto 21Compuesto 24Compuesto 27Compuesto 30Compuesto 33Compuesto 34 Compuesto 35 Compuesto 36imagen6 imagen7 imagen8 imagen9 Compuesto 103 Compuesto 104 Compuesto 105Compuesto 106 Compuesto 107 Compuesto 108Compuesto 109 Compuesto 110 Compuesto 111Compuesto 112 Compuesto 113 Compuesto 114Compuesto 115 Compuesto 116 Compuesto 117Compuesto 118 Compuesto 119 Compuesto 120imagen10 Compuesto 136 Compuesto 137 Compuesto 138Compuesto 139 Compuesto 140 Compuesto 141Compuesto 142 Compuesto 143 Compuesto 144Compuesto 145 Compuesto 146 Compuesto 147Compuesto 148 Compuesto 149 Compuesto 150Compuesto 151 Compuesto 152 Compuesto 153imagen11 imagen12 Compuesto 190 Compuesto 191 Compuesto 192Compuesto 193 Compuesto 194 Compuesto 195Compuesto 196 Compuesto 197 Compuesto 198Compuesto 199 Compuesto 200 Compuesto 201Compuesto 202 Compuesto 203 Compuesto 204Compuesto 205 Compuesto 206 Compuesto 207imagen13 Compuesto 226 Compuesto 227 Compuesto 228Compuesto 229 Compuesto 230 Compuesto 231Compuesto 232 Compuesto 233 Compuesto 234Compuesto 235 Compuesto 236 Compuesto 237Compuesto 238 Compuesto 239 Compuesto 240Compuesto 241 Compuesto 242 Compuesto 243imagen14 imagen15 imagen16 - 11. Un compuesto, en el que el compuesto es uno de los compuestos siguientes:
- Compuesto 10
- Compuesto 16 Compuesto 23
- Compuesto 25
- Compuesto 26 Compuesto 30
- Compuesto 35
- Compuesto 36 Compuesto 80
Compuesto 81 Compuesto 82 Compuesto 84imagen17
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2009/056937 WO2011034518A1 (en) | 2009-09-15 | 2009-09-15 | Hcv protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2588204T3 true ES2588204T3 (es) | 2016-10-31 |
Family
ID=43758907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09849606.0T Active ES2588204T3 (es) | 2009-09-15 | 2009-09-15 | Inhibidores de la proteasa de HCV |
Country Status (21)
Country | Link |
---|---|
US (1) | US8389560B2 (es) |
EP (1) | EP2477980B1 (es) |
JP (1) | JP5702388B2 (es) |
KR (1) | KR101670319B1 (es) |
AU (1) | AU2009352688B2 (es) |
CA (1) | CA2774145C (es) |
CY (1) | CY1118136T1 (es) |
DK (1) | DK2477980T3 (es) |
EA (1) | EA022118B1 (es) |
ES (1) | ES2588204T3 (es) |
HR (1) | HRP20161025T1 (es) |
HU (1) | HUE030402T2 (es) |
LT (1) | LT2477980T (es) |
NZ (1) | NZ599133A (es) |
PL (1) | PL2477980T3 (es) |
PT (1) | PT2477980T (es) |
SG (1) | SG179566A1 (es) |
SI (1) | SI2477980T1 (es) |
SM (1) | SMT201600291B (es) |
WO (1) | WO2011034518A1 (es) |
ZA (1) | ZA201202631B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
EA201170441A1 (ru) * | 2008-10-15 | 2012-05-30 | Интермьюн, Инк. | Терапевтические противовирусные пептиды |
EA201290128A1 (ru) * | 2009-09-28 | 2013-01-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликации вируса гепатита с |
WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN102911254A (zh) * | 2011-08-02 | 2013-02-06 | 上海唐润医药科技有限公司 | Hcv蛋白酶抑制剂 |
EP2802595B1 (en) * | 2012-01-11 | 2016-01-06 | AbbVie Inc. | Processes for making hcv protease inhibitors |
KR102127406B1 (ko) | 2012-09-20 | 2020-06-29 | 유디씨 아일랜드 리미티드 | 전자 응용을 위한 아자디벤조푸란 |
JP2015533124A (ja) | 2012-10-08 | 2015-11-19 | アッヴィ・インコーポレイテッド | Hcvプロテアーゼ阻害剤を作製するのに有用な化合物 |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN104557954A (zh) * | 2013-10-16 | 2015-04-29 | 上海唐润医药科技有限公司 | 抗hcv的大环化合物 |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
CN104447952A (zh) * | 2014-12-11 | 2015-03-25 | 上海唐润医药科技有限公司 | 丙肝病毒蛋白酶抑制剂及其合成方法 |
CN108727417B (zh) * | 2015-02-05 | 2021-10-08 | 爱博新药研发(上海)有限公司 | 多环化合物钠盐及其多晶型、制备方法及应用 |
JP2019521995A (ja) * | 2016-06-22 | 2019-08-08 | 出光興産株式会社 | 有機発光ダイオード用の特定位置が置換されたベンゾフロ−又はベンゾチエノキノリン |
US10004719B1 (en) * | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
WO2018222172A1 (en) * | 2017-05-30 | 2018-12-06 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4555508A (en) | 1984-03-02 | 1985-11-26 | Usv Pharmaceutical Corp. | Antihypertensive spiro-cyclic compounds |
AU2933797A (en) | 1996-05-10 | 1997-12-05 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
US5876984A (en) | 1996-09-25 | 1999-03-02 | Shionogi & Co., Ltd | Sequiterpene derivatives having antiviral activity |
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
JP4690545B2 (ja) | 1998-03-31 | 2011-06-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US20030073618A1 (en) | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
US20020182647A1 (en) | 2001-04-30 | 2002-12-05 | Emmert-Buck Michael R. | Histoscreen method |
CN100402549C (zh) | 2001-07-11 | 2008-07-16 | 沃泰克斯药物股份有限公司 | 桥连二环的丝氨酸蛋白酶抑制剂 |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2473070C (en) | 2002-01-23 | 2009-10-13 | Schering Corporation | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
NZ561851A (en) | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
WO2004043339A2 (en) | 2002-05-20 | 2004-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
US7601367B2 (en) | 2002-05-28 | 2009-10-13 | Mirus Bio Llc | Compositions and processes using siRNA, amphipathic compounds and polycations |
CA2504385C (en) | 2002-11-01 | 2012-12-18 | Abbott Laboratories | Thiadiazine compounds and uses thereof |
KR100940619B1 (ko) | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
TW200510391A (en) | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
EP2332935A1 (en) | 2003-04-11 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
ES2386161T3 (es) | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
US8008267B2 (en) | 2003-06-11 | 2011-08-30 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
CN1852920B (zh) | 2003-07-18 | 2010-12-15 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
AU2004274468B2 (en) | 2003-09-18 | 2009-07-23 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
MXPA06003141A (es) | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c. |
JP4525982B2 (ja) | 2003-09-26 | 2010-08-18 | シェーリング コーポレイション | C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
JP2007532479A (ja) | 2003-11-20 | 2007-11-15 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター |
AU2004298498B2 (en) | 2003-12-11 | 2008-09-11 | Schering Corporation | Inhibitors of hepatitis C virus NS3/NS4a serine protease |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
CA2577831A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
EP1898941A2 (en) | 2005-06-02 | 2008-03-19 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
US20070207949A1 (en) | 2005-06-02 | 2007-09-06 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
WO2008022006A2 (en) * | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
US20080267917A1 (en) | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
WO2008134395A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
WO2009055335A2 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
-
2009
- 2009-09-15 US US12/559,818 patent/US8389560B2/en active Active
- 2009-09-15 KR KR1020127009259A patent/KR101670319B1/ko active IP Right Grant
- 2009-09-15 ES ES09849606.0T patent/ES2588204T3/es active Active
- 2009-09-15 NZ NZ599133A patent/NZ599133A/xx not_active IP Right Cessation
- 2009-09-15 EP EP09849606.0A patent/EP2477980B1/en active Active
- 2009-09-15 AU AU2009352688A patent/AU2009352688B2/en not_active Ceased
- 2009-09-15 JP JP2012529723A patent/JP5702388B2/ja not_active Expired - Fee Related
- 2009-09-15 DK DK09849606.0T patent/DK2477980T3/en active
- 2009-09-15 CA CA2774145A patent/CA2774145C/en not_active Expired - Fee Related
- 2009-09-15 WO PCT/US2009/056937 patent/WO2011034518A1/en active Application Filing
- 2009-09-15 SG SG2012018412A patent/SG179566A1/en unknown
- 2009-09-15 LT LTEP09849606.0T patent/LT2477980T/lt unknown
- 2009-09-15 HU HUE09849606A patent/HUE030402T2/en unknown
- 2009-09-15 EA EA201270423A patent/EA022118B1/ru unknown
- 2009-09-15 PT PT98496060T patent/PT2477980T/pt unknown
- 2009-09-15 PL PL09849606T patent/PL2477980T3/pl unknown
- 2009-09-15 SI SI200931505A patent/SI2477980T1/sl unknown
-
2012
- 2012-04-12 ZA ZA2012/02631A patent/ZA201202631B/en unknown
-
2016
- 2016-08-16 HR HRP20161025TT patent/HRP20161025T1/hr unknown
- 2016-08-29 SM SM201600291T patent/SMT201600291B/it unknown
- 2016-08-31 CY CY20161100856T patent/CY1118136T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SMT201600291B (it) | 2016-11-10 |
LT2477980T (lt) | 2016-09-26 |
SG179566A1 (en) | 2012-05-30 |
SI2477980T1 (sl) | 2017-01-31 |
CY1118136T1 (el) | 2017-06-28 |
PL2477980T3 (pl) | 2017-02-28 |
HRP20161025T1 (hr) | 2016-11-04 |
KR20120110091A (ko) | 2012-10-09 |
EP2477980A1 (en) | 2012-07-25 |
DK2477980T3 (en) | 2016-09-12 |
EA022118B1 (ru) | 2015-11-30 |
AU2009352688B2 (en) | 2014-04-17 |
CA2774145A1 (en) | 2011-03-24 |
PT2477980T (pt) | 2016-08-31 |
CA2774145C (en) | 2015-10-27 |
US8389560B2 (en) | 2013-03-05 |
US20110065737A1 (en) | 2011-03-17 |
WO2011034518A1 (en) | 2011-03-24 |
KR101670319B1 (ko) | 2016-10-28 |
HUE030402T2 (en) | 2017-05-29 |
EP2477980A4 (en) | 2013-05-01 |
AU2009352688A1 (en) | 2012-04-26 |
ZA201202631B (en) | 2012-12-27 |
JP2013504616A (ja) | 2013-02-07 |
JP5702388B2 (ja) | 2015-04-15 |
EA201270423A1 (ru) | 2012-09-28 |
NZ599133A (en) | 2013-10-25 |
EP2477980B1 (en) | 2016-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2588204T3 (es) | Inhibidores de la proteasa de HCV | |
AR052558A1 (es) | Derivados de tiazol-4-carboxamida como antagonistas de mglur5 | |
AR105340A2 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden | |
UY29016A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
AR108819A2 (es) | Formas polimórficas de un inhibidor macrocíclico de vhc | |
ATE478889T1 (de) | Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease | |
AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
EP1771454A4 (en) | PEPTIDE ANALOGUE AS HEPATITIS C HEMMER | |
DK1481000T3 (da) | Nye peptider som NS3-serin-proteasehæmmere af hepatitis C-virus | |
AR038382A1 (es) | Compuesto inhibidor de la hepatitis c | |
DE602005025363D1 (de) | Substituierte amide als inhibitoren der beta-sekretase | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
CY1112914T1 (el) | Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης | |
HK1099028A1 (en) | Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease | |
ZA200607104B (en) | Compounds as inhibitors of hepatitis C virus NS3 Serine protease | |
AR049125A1 (es) | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. | |
WO2004101602A3 (en) | Hepatitis c inhibitor peptide analogs | |
ES2543607T3 (es) | Ciertas amidas sustituidas, método de obtención, y método de su uso | |
IS8324A (is) | Hraðuppleysandi samsetning af kalsíum viðtaka-virku efnasambandi | |
AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
ATE389638T1 (de) | Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3- | |
AR045805A1 (es) | Quinolonas y naftridonas 7- amino alquidenil - heterociclicas | |
ATE405553T1 (de) | Heterocyclische verbindungen als inhibitoren von faktor viia | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
CO6260077A2 (es) | Pirimidinas biciclicas fusionadas |